M&A
confidence high
sentiment positive
materiality 0.75
Veracyte acquires Convergent Genomics for $150M cash plus $30M milestones
VERACYTE, INC.
- Veracyte paid $150M upfront cash for Convergent, plus up to $30M milestone payments tied to UroAmp publications and reimbursement.
- Adds UroAmp urinary tumor DNA (utDNA) platform for bladder cancer, clinically validated in NMIBC for therapy monitoring and surveillance.
- Veracyte expects to commercialize initial UroAmp test in late 2028, subject to reimbursement timelines; plans additional indications.
- RUMBLE study: utDNA-positive patients post-BCG had 12-month recurrence-free survival 25% vs 91% for utDNA-negative patients.
- Veracyte maintains 2026 adjusted EBITDA guidance, including Convergent's ongoing operating expenses.